Advertisement

Molecular Mechanisms of the Actions of Brain Peptide-Containing Drugs: Cortexin

  • N. V. GulyaevaEmail author
Article
  • 1 Downloads

This article considers new data on the key molecular mechanisms which may underlie the neuroprotective properties of multicomponent organ-specific medicinal formulations consisting of peptide hydrolysates extracted from animal brains. Such formulations, including cortexin, are currently quite widely used in the treatment of cerebral pathologies. The potential molecular mechanisms of the neuroprotective effects of cortexin are shown to be diverse and to influence key processes underlying neuroplasticity: signal transduction, energy metabolism, proteolytic modification of proteins, brain cell structures, and neuroinflammation processes. The pleiotropic nature of the mechanisms of action of cortexin results from the composition of the formulation, which contains a multitude of different neuropeptides. The tissue specificity of the molecular mechanisms identified here to a significant extent determines the efficacy of the agent in cerebral pathologies.

Keywords

peptide hydrolysates neuroplasticity cortexin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    K. A. Witt, T. J. Gillespie, J. D. Huber, et al., “Peptide drug modifications to enhance bioavailability and blood–brain barrier permeability,” Peptides, 22, No. 12, 2329–2343 (2001), https://doi.org/ https://doi.org/10.1016/s0196-9781(01)00537-x.CrossRefGoogle Scholar
  2. 2.
    L. Malavolta and F. R. Cabral, “Peptides: important tools for the treatment of central nervous system disorders,” Neuropeptides, 45, No. 5, 309–316 (2011), https://doi.org/ https://doi.org/10.1016/j.npep.2011.03.001.CrossRefGoogle Scholar
  3. 3.
    I. Gozes, “Neuroprotective peptide drug delivery and development: potential new therapeutics,” Trends Neurosci., 24, No. 12, 700–705 (2001), https://doi.org/ https://doi.org/10.1016/s0166-2236(00)01931-7.CrossRefGoogle Scholar
  4. 4.
    N. V. Gulyaeva, “Molecular mechanisms of neuroplasticity: an expanding universe,” Biochemistry, 82, No. 3, 237–242 (2017), https://doi.org/ https://doi.org/10.1134/S0006297917030014.CrossRefGoogle Scholar
  5. 5.
    I. P. Ashmarin, “Potentials for the practical application and some basic studies of small regulatory peptides,” Vopr. Med. Khim., 30, No. 3, 2–7 (1984).PubMedGoogle Scholar
  6. 6.
    I. P. Ashmarin, S. A. Chepurnov, and A. P. Kulaichev, “Cascade unidirectional regulatory processes of short-lived peptides,” Fiziol. Zh,, 75, No. 5, 627–632 (1989).Google Scholar
  7. 7.
    S. V. Koroleva and I. P. Ashmarin, “A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents,” Neurosci. Behav. Physiol., 36, No. 2, 157–162 (2006).CrossRefGoogle Scholar
  8. 8.
    O. A. Gomazkov, “Cortexin: molecular mechanisms and targets for neuroprotective activity,” Zh. Nevrol. Psikhiat., 115, No. 8, 99–104 (2015).CrossRefGoogle Scholar
  9. 9.
    M. Brainin, “Cerebrolysin: a multi-target drug for recovery after stroke,” Expert Rev. Neurother., 18, 1–7 (2018), https://doi.org/ https://doi.org/10.1080/14737175.2018.1500459.CrossRefGoogle Scholar
  10. 10.
    M. Yu. Stepanichev, M. V. Onufriev, D. I. Peregud, et al., “Effects of cortexin on free-radical oxidation and inflammatory processes in rats with normal and accelerated aging,” Neirokhimiya, 35, No. 2, 187–198 (2018), https://doi.org/ https://doi.org/10.7868/S1027813318020127.
  11. 11.
    V. A. Aniol, Yu. A. Novitskaya, T. N. Borodina, et al., “Assessment of the antiepileptic effects of cortexin in a model of convulsive activity,” Zh. Nevrol. Psikhiat., 111, No. 12, 68–73 (2011).Google Scholar
  12. 12.
    N. V. Gulyaeva, “Staging of changes in neuroplasticity in epileptogenesis using temporal epilepsy as an example,” Zh. Nevrol. Psikhiat. (spec. iss.), 117, No. 9, 10–16 (2017), https://doi.org/ https://doi.org/10.17116/jnevro20171179210-16.CrossRefGoogle Scholar
  13. 13.
    A. A. Yakovlev and N. V. Gulyaeva, “The pleiotropic functions of brain proteinases: methodological approaches to studies and the search for the substrates of caspases,” Biokhimiya, 76, No. 10, 1079–1086 (2011), https://doi.org/ https://doi.org/10.1134/S0006297911100014.CrossRefGoogle Scholar
  14. 14.
    A. A. Yakovlev and N. V. Gulyaeva, “Possible role of proteases in preconditioning of brain cells to pathological conditions,” Biochemistry, 80, No. 2, 163–171 (2015), https://doi.org/ https://doi.org/10.1134/S00062979.15020030.
  15. 15.
    A. A. Yakovlev, A. A. Lyzhin, L. G. Khaspekov, et al., “Peptide drug cortexin inhibits brain caspase-8,” Biomed. Khim., 63, No. 1, 27–31 (2017), https://doi.org/ https://doi.org/10.18097/PBMC2017630127.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Higher Nervous Activity and NeurophysiologyRussian Academy of SciencesMoscowRussia
  2. 2.Solov’ev Scientific and Applied Psychoneurology CenterMoscow Health DepartmentMoscowRussia

Personalised recommendations